AP NEWS

Chlamydia Infections - Pipeline Insight, 2019 - ResearchAndMarkets.com

January 31, 2019

DUBLIN--(BUSINESS WIRE)--Jan 31, 2019--The “Chlamydia Infections - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Chlamydia Infections - Pipeline Insight, 2019 offers a comprehensive insight of the pipeline (under development) therapeutics scenario and growth prospects across Chlamydia Infections development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope

The report provides a snapshot of the pipeline development for Chlamydia Infections The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for Chlamydia Infections The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Chlamydia Infections The report also covers the dormant and discontinued pipeline projects related to Chlamydia Infections

Topics Covered

1. Report Introduction

2. Chlamydia Infections Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Chlamydia Infections

4. Comparative Analysis

5. Products in Clinical Stage

Product Description Research and Development Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

Product Description Research and Development Product Development Activities

7. Therapeutic Assessment

Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type

8. Inactive Products

Product Description Research and Development Product Development Activities

Companies Featured

Abera Bioscience AB Evofem Inc. Lead Discovery Center GmbH Merck & Co. Inc. NanoBio Corp. Prokarium Ltd. QureTech Bio AB SATT IDF Innov S.A.S Selecta Biosciences Inc. SIGA Technologies Inc.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/2rffbq/chlamydia?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190131005810/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Infectious Diseases Drugs,Sexual and Reproductive Health Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/31/2019 01:43 PM/DISC: 01/31/2019 01:43 PM

http://www.businesswire.com/news/home/20190131005810/en

AP RADIO
Update hourly